1. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org . Accessed 15 Mar 2015.
2. Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., et al. (2014). Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine, 370(16), 1483–1493. doi: 10.1056/NEJMoa1316366 .
3. Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., et al. (2014). Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine, 370(20), 1889–1898. doi: 10.1056/NEJMoa1402454 .
4. Braitstein, P., Li, K., Kerr, T., Montaner, J. S., Hogg, R. S., & Wood, E. (2006). Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone. AIDS Care, 18(7), 690–693. doi: 10.1080/09540120500359330 .
5. Chen, E. Y., North, C. S., Fatunde, O., Bernstein, I., Salari, S., Day, B., & Jain, M. K. (2013). Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. Journal of Viral Hepatitis, 10(1), 111.